Theoretical and Experimental Assessment of the Solubility Advantage of Glassy Pharmaceuticals over Their Corresponding Crystalline Counterparts
Posted on December 17, 2013
By: Sharad Murdande, Principal Scientist
Pfizer
Introduction There is growing interest in advancing amorphous or stabilised amorphous forms as a practical solubilisation approach.1-3 Despite the growing interest in the use of amorphous drug forms to enhance solubility and/or dissolution rate, there is a lack of available methods to measure or pr...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
advancing amorphous, Crystalline, dissolution, Glassy Pharmaceuticals, Modulated Temperature Differential Scanning Calorimeter, nanocrystals, Pfizer, Rapid Crystallisers, solubility, stabilised amorphous
Related Product Videos
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
